Company news
Veracyte, Inc. (NASDAQ:VCYT) news
Every Veracyte, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 5
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
May 4, 2021
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
April 29, 2021
Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis
April 27, 2021
Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021
April 20, 2021
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference
April 19, 2021
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
April 15, 2021
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
April 14, 2021
Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
April 2, 2021
Veracyte Appoints Muna Bhanji to Its Board of Directors
March 22, 2021
Veracyte Completes Acquisition of Decipher Biosciences
March 15, 2021
Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
February 17, 2021
Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
February 10, 2021
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 9, 2021
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
February 4, 2021
Veracyte Announces Proposed Public Offering of Common Stock
February 3, 2021
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
December 21, 2020
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
December 16, 2020
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
December 15, 2020
Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
December 3, 2020
Veracyte Announces New General Manager Structure to Advance Global Expansion
November 17, 2020
Veracyte Announces Third Quarter 2020 Financial Results
November 2, 2020
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
October 30, 2020
Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
October 22, 2020
Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020
October 19, 2020
Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020
October 14, 2020
Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020
October 7, 2020
Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
September 24, 2020
Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
September 14, 2020
Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
September 11, 2020
Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year
August 24, 2020
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
August 5, 2020
Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
August 4, 2020
Veracyte Announces Second Quarter 2020 Financial Results
July 30, 2020
Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
July 29, 2020
Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary
July 27, 2020
Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020
July 16, 2020
Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
June 11, 2020
Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay
June 9, 2020
Veracyte Announces First Quarter 2020 Financial Results
May 6, 2020
Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
May 1, 2020
CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
April 23, 2020
Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
April 16, 2020
Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations
April 7, 2020
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
April 1, 2020
Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
March 2, 2020
Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
February 25, 2020
Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020
February 6, 2020
Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
January 8, 2020
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
December 3, 2019
Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
November 2, 2019